Bioorthogonal Chemistry: From Bench to Bedside | Carolyn Bertozzi

Added:

Translational Hurdles and Pharmacokinetic Limitations of In Vivo Bioorthogonal Reactions

While bioorthogonal chemistry has revolutionized molecular labeling in vitro, its translation to human clinical therapies faces significant skepticism and practical hurdles. Critics highlight that the reaction kinetics of bioorthogonal pairs, such as strain-promoted azide-alkyne cycloaddition (SPAAC), are often too slow at the highly diluted concentrations found in the human body. Successfully delivering two separate components—the pre-targeted tag and the reactive probe—to the exact same disease site at the right time poses immense pharmacokinetic challenges. Additionally, there are concerns regarding the potential toxicity, immunogenicity, and off-target reactivity of synthetic, non-natural functional groups (like azides or tetrazines) during prolonged exposure. Consequently, some pharmaceutical scientists argue that established single-component platforms, such as traditional antibody-drug conjugates (ADCs) or genetically encoded systems, remain more viable and less complex pathways for targeted drug delivery than multi-step in vivo bioorthogonal systems.

Fundamentals of organic chemistry, particularly functional groups, covalent bond formation, and basic reaction mechanisms like cycloadditions.
Basic cell biology concepts, with an emphasis on the structure and function of the cell membrane, proteins, and carbohydrates (glycans).
The concept of bioconjugation and the inherent challenges of conducting selective chemical reactions in complex, aqueous biological environments.
An understanding of click chemistry, specifically the copper-catalyzed azide-alkyne cycloaddition (CuAAC), and why copper toxicity limits its use in living systems.
Advanced application of bioorthogonal chemistry in targeted therapeutics, such as Antibody-Drug Conjugates (ADCs) and prodrug activation.
The role of cell-surface glycosylation (glycobiology) in cancer immunology and how targeting glycans can lead to novel immunotherapies.
In vivo molecular imaging techniques (like PET, SPECT, and fluorescence imaging) that rely on bioorthogonal labeling to track biological processes in real-time.
Translational medicine workflows, focusing on the safety, pharmacokinetic, and regulatory challenges of moving chemical tools from in vitro systems to human clinical trials.
6K views165likes1:18:53@hertzfoundationOriginal Release: 2023-09-26

Bioorthogonal chemistry refers to chemical reactions designed to occur selectively in living biological systems without interfering with natural biological processes. This field emerged from the need to study sugar molecules (glycans) in living cells, as traditional chemical reactions cannot be easily controlled in complex biological environments. The foundational concept involves identifying chemical functional groups that do not exist in nature, allowing chemists to perform reactions in living organisms for applications such as imaging, drug delivery, and therapeutic targeting. Key examples include the Staudinger ligation (azide-phosphine reaction), copper-free click chemistry using strained alkynes, and tetrazine ligation for rapid bioorthogonal reactions. These technologies have been translated into clinical applications including site-specific antibody-drug conjugates for cancer treatment and targeted drug delivery systems.